Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

336 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper).
Wiendl H, Gold R, Berger T, Derfuss T, Linker R, Mäurer M, Aktas O, Baum K, Berghoff M, Bittner S, Chan A, Czaplinski A, Deisenhammer F, Di Pauli F, Du Pasquier R, Enzinger C, Fertl E, Gass A, Gehring K, Gobbi C, Goebels N, Guger M, Haghikia A, Hartung HP, Heidenreich F, Hoffmann O, Kallmann B, Kleinschnitz C, Klotz L, Leussink VI, Leutmezer F, Limmroth V, Lünemann JD, Lutterotti A, Meuth SG, Meyding-Lamadé U, Platten M, Rieckmann P, Schmidt S, Tumani H, Weber F, Weber MS, Zettl UK, Ziemssen T, Zipp F; ‘Multiple Sclerosis Therapy Consensus Group’ (MSTCG). Wiendl H, et al. Among authors: zettl uk. Ther Adv Neurol Disord. 2021 Aug 18;14:17562864211039648. doi: 10.1177/17562864211039648. eCollection 2021. Ther Adv Neurol Disord. 2021. PMID: 34422112 Free PMC article. Review.
Cerebrospinal fluid biomarkers in multiple sclerosis.
Tumani H, Hartung HP, Hemmer B, Teunissen C, Deisenhammer F, Giovannoni G, Zettl UK; BioMS Study Group. Tumani H, et al. Among authors: zettl uk. Neurobiol Dis. 2009 Aug;35(2):117-27. doi: 10.1016/j.nbd.2009.04.010. Epub 2009 May 5. Neurobiol Dis. 2009. PMID: 19426803 Review.
Animal models of multiple sclerosis--potentials and limitations.
Mix E, Meyer-Rienecker H, Hartung HP, Zettl UK. Mix E, et al. Among authors: zettl uk. Prog Neurobiol. 2010 Nov;92(3):386-404. doi: 10.1016/j.pneurobio.2010.06.005. Epub 2010 Jun 15. Prog Neurobiol. 2010. PMID: 20558237 Free PMC article. Review.
Revised McDonald criteria: the persisting importance of cerebrospinal fluid analysis.
Tumani H, Deisenhammer F, Giovannoni G, Gold R, Hartung HP, Hemmer B, Hohlfeld R, Otto M, Stangel M, Wildemann B, Zettl UK. Tumani H, et al. Among authors: zettl uk. Ann Neurol. 2011 Sep;70(3):520; author reply 521. doi: 10.1002/ana.22508. Epub 2011 Jun 27. Ann Neurol. 2011. PMID: 21710627 No abstract available.
Independent replication of STAT3 association with multiple sclerosis risk in a large German case-control sample.
Lill CM, Schjeide BM, Akkad DA, Blaschke P, Winkelmann A, Gerdes LA, Hoffjan S, Luessi F, Dörner T, Li SC, Steinhagen-Thiessen E, Lindenberger U, Chan A, Hartung HP, Aktas O, Lohse P, Kümpfel T, Kubisch C, Epplen JT, Zettl UK, Bertram L, Zipp F. Lill CM, et al. Among authors: zettl uk. Neurogenetics. 2012 Feb;13(1):83-6. doi: 10.1007/s10048-011-0305-6. Epub 2011 Nov 18. Neurogenetics. 2012. PMID: 22095036
Vaccination against infection in patients with multiple sclerosis.
Loebermann M, Winkelmann A, Hartung HP, Hengel H, Reisinger EC, Zettl UK. Loebermann M, et al. Among authors: zettl uk. Nat Rev Neurol. 2012 Jan 24;8(3):143-51. doi: 10.1038/nrneurol.2012.8. Nat Rev Neurol. 2012. PMID: 22270022 Review.
Treatment de-escalation after mitoxantrone therapy: results of a phase IV, multicentre, open-label, randomized study of subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis.
Rieckmann P, Heidenreich F, Sailer M, Zettl UK, Zessack N, Hartung HP, Gold R. Rieckmann P, et al. Among authors: zettl uk. Ther Adv Neurol Disord. 2012 Jan;5(1):3-12. doi: 10.1177/1756285611428503. Ther Adv Neurol Disord. 2012. PMID: 22276072 Free PMC article.
Closing the case of APOE in multiple sclerosis: no association with disease risk in over 29 000 subjects.
Lill CM, Liu T, Schjeide BM, Roehr JT, Akkad DA, Damotte V, Alcina A, Ortiz MA, Arroyo R, Lopez de Lapuente A, Blaschke P, Winkelmann A, Gerdes LA, Luessi F, Fernadez O, Izquierdo G, Antigüedad A, Hoffjan S, Cournu-Rebeix I, Gromöller S, Faber H, Liebsch M, Meissner E, Chanvillard C, Touze E, Pico F, Corcia P; ANZgene Consortium,{dagger}; Dörner T, Steinhagen-Thiessen E, Baeckman L, Heekeren HR, Li SC, Lindenberger U, Chan A, Hartung HP, Aktas O, Lohse P, Kümpfel T, Kubisch C, Epplen JT, Zettl UK, Fontaine B, Vandenbroeck K, Matesanz F, Urcelay E, Bertram L, Zipp F. Lill CM, et al. Among authors: zettl uk. J Med Genet. 2012 Sep;49(9):558-62. doi: 10.1136/jmedgenet-2012-101175. J Med Genet. 2012. PMID: 22972946
MANBA, CXCR5, SOX8, RPS6KB1 and ZBTB46 are genetic risk loci for multiple sclerosis.
International Multiple Sclerosis Genetics Consortium; Lill CM, Schjeide BM, Graetz C, Ban M, Alcina A, Ortiz MA, Pérez J, Damotte V, Booth D, Lopez de Lapuente A, Broer L, Schilling M, Akkad DA, Aktas O, Alloza I, Antigüedad A, Arroyo R, Blaschke P, Buttmann M, Chan A, Compston A, Cournu-Rebeix I, Dörner T, Epplen JT, Fernández Ó, Gerdes LA, Guillot-Noël L, Hartung HP, Hoffjan S, Izquierdo G, Kemppinen A, Kroner A, Kubisch C, Kümpfel T, Li SC, Lindenberger U, Lohse P, Lubetzki C, Luessi F, Malhotra S, Mescheriakova J, Montalban X, Papeix C, Paredes LF, Rieckmann P, Steinhagen-Thiessen E, Winkelmann A, Zettl UK, Hintzen R, Vandenbroeck K, Stewart G, Fontaine B, Comabella M, Urcelay E, Matesanz F, Sawcer S, Bertram L, Zipp F. International Multiple Sclerosis Genetics Consortium, et al. Among authors: zettl uk. Brain. 2013 Jun;136(Pt 6):1778-82. doi: 10.1093/brain/awt101. Brain. 2013. PMID: 23739915 Free PMC article.
336 results